Pacira BioSciences (PCRX) Enterprise Value (2010 - 2026)

Pacira BioSciences' Enterprise Value history runs 17 years deep, the most recent figure standing at -$202.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 59.04% year-over-year to -$202.2 million in Q1 2026; TTM through Mar 2026 was -$202.2 million, a 59.04% increase from a year earlier, with the FY2025 full-year figure at -$238.4 million, up 50.8% from the prior year.
• Enterprise Value advanced to -$202.2 million in Q1 2026 per PCRX's latest filing, from -$238.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$174.0 million in Q1 2023 and bottomed at -$493.6 million in Q1 2025.
• The 5-year median for Enterprise Value is -$316.4 million (2022), against an average of -$328.8 million.
• Across the five-year window, Enterprise Value jumped 61.52% in 2023 and tumbled 92.96% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$288.7 million in 2022, then gained by 3.49% to -$278.6 million in 2023, then plunged by 73.96% to -$484.6 million in 2024, then surged by 50.8% to -$238.4 million in 2025, then increased by 15.2% to -$202.2 million in 2026.
• Per Business Quant, the three latest PCRX Enterprise Value figures stand at -$202.2 million (Q1 2026), -$238.4 million (Q4 2025), and -$246.3 million (Q3 2025).